Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Moodys
AstraZeneca
Express Scripts
Mallinckrodt
Johnson and Johnson
McKesson

Last Updated: November 22, 2019

DrugPatentWatch Database Preview

Details for Patent: 6,861,409

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 6,861,409 protect, and when does it expire?

Patent 6,861,409 protects MACRILEN and is included in one NDA.

This patent has sixty-two patent family members in twenty-nine countries.

Summary for Patent: 6,861,409
Title: Growth hormone secretagogues
Abstract:The invention relates to compounds of formula I ##STR1## which are useful for elevating the plasma level of growth hormone in a mammal as well for the treatment of growth hormone secretion deficiency, growth retardation in child and metabolic disorders associated with growth hormone secretion deficiency.
Inventor(s): Martinez; Jean (Saussan, FR), Fehrentz; Jean-Alain (St. Nazaire de Pezan, FR), Guerlavais; Vincent (Montpellier, FR)
Assignee: Zentaris AG (Frankfurt am Main, DE)
Application Number:09/880,498
Patent Claim Types:
see list of patent claims
Use; Composition; Compound;

Drugs Protected by US Patent 6,861,409

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Novo MACRILEN macimorelin acetate FOR SOLUTION;ORAL 205598-001 Dec 20, 2017 RX Yes Yes   Start Trial   Start Trial Y Y A METHOD FOR THE DIAGNOSIS OF ADULT GROWTH HORMONE DEFICIENCY BY MEASURING THE LEVEL OF GROWTH HORMONE AFTER ORAL ADMINISTRATION OF MACIMORELIN   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 6,861,409

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 029941   Start Trial
Austria 302181   Start Trial
Austria 362472   Start Trial
Austria 370119   Start Trial
Australia 2001266066   Start Trial
Australia 6606601   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson
Mallinckrodt
Dow
Moodys
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.